BLA

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT)

Retrieved on: 
Monday, April 8, 2024
Radiation, CKPT, Patient, SAN, News, LLP, Acquisition, Checkpoint, CMO, FDA, BLA, Person, Pharmaceutical industry

SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.

Key Points: 
  • SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Retrieved on: 
Monday, April 8, 2024
Arm, Retinitis pigmentosa, Disease, Patient, Lux, RP, IND, Clutch (eggs), Vaccine, Food, RHO, FDA, BLA, Pharmaceutical industry

“OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.

Key Points: 
  • “OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.
  • Until now, there has been only one marketed product to treat one of the 100 gene mutations associated with RP.
  • In the Phase 1/2 OCU400 clinical trial, a Multi-Luminance Mobility Testing (MLMT) scale was the primary functional endpoint.
  • With the initiation of the Phase 3 clinical trial, OCU400 remains on track for the 2026 BLA approval target.

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

Retrieved on: 
Monday, April 8, 2024
SOC, CDMO, Orphan drug, Letter, Cell, Science, Bone marrow, Disease, Partnership, Caregiver, Hypoplastic left heart syndrome, Patient, Fast Track, Research, Microsoft Exchange Server, Standard of care, Security (finance), CLEAR, Surgeon, Regenerative medicine, FDA, BLA, Development, Pharmaceutical industry

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.

Key Points: 
  • MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.
  • Today, I am excited to update you on our overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
  • Our focus remains steadfast on raising the funds necessary to continue our operations and delivering transformative solutions to patients and creating sustainable value for our shareholders.
  • In 2024, we are focusing our efforts on two of our most promising programs: Hypoplastic Left Heart Syndrome (HLHS); and Alzheimer’s Disease.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 6, 2024
Sickle cell disease, Biotechnology, Luna Innovations, Bluebird, Blue, DSM-IV codes, Patient, Defendant, History, News, Cancer, Bank statement, False, Complaint, P.C, Elivaldogene autotemcel, File, SCD, FDA, BLA, Food

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.
  • For more information on the Luna Innovations class action go to: https://bespc.com/cases/LUNA

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, April 5, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL

Retrieved on: 
Tuesday, April 2, 2024
Certification, MAA, B-ALL, Patient, Orphan, ALL, EMA, GMP, European Medicines Agency, MHRA, Therapy, Priority, Marketing, FDA, BLA, PDUFA, Pharmaceutical industry

Obe-cel is Autolus’ lead investigational chimeric antigen receptor (CAR) T cell therapy, for the treatment of patients with relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL).

Key Points: 
  • Obe-cel is Autolus’ lead investigational chimeric antigen receptor (CAR) T cell therapy, for the treatment of patients with relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL).
  • The MAA submission was based on data from the pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL.
  • Autolus’ Nucleus site has recently received the formal certification from the MHRA following a full inspection of the site in February 2024.
  • The MHRA issued two new GMP certificates to cover both clinical and commercial manufacture from the site.

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, April 1, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird, Clinical, SAN, DSM-IV codes, Patient, History, News, LLP, Cancer, Commercial, Complaint, BLUE, File, SCD, FDA, BLA, Bluebird bio, Food, Person, Pharmaceutical industry

SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.

Key Points: 
  • SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.
  • Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird bio, SAN, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Pharmaceutical industry

), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.